Bovine papillomavirus-like particles presenting conserved epitopes from membrane-proximal external region of HIV-1 gp41 induced mucosal and systemic antibodies

Vaccine

Volumn 31, Issue 46, 2013, Pages 5422-5429

  Zhai, Yougang ^a   Zhong, Zhenyu ^a   Zariffard, Mohammadreza ^b   Spear, Gregory T ^b   Qiao, Liang ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bovine papillomavirus like particle; HIV 1; Membrane proximal external region; Mucosal; Neutralizing antibody; Vaccine

Indexed keywords

GLYCOPROTEIN GP 41; MONOCLONAL ANTIBODY 2F5; NEUTRALIZING ANTIBODY; VIRUS ENVELOPE PROTEIN; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; ELECTRON MICROSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNIZATION; IMMUNOGENICITY; MEMBRANE PROXIMAL EXTERNAL REGION; MOUSE; NONHUMAN; PAPILLOMA VIRUS; PRIORITY JOURNAL; PROTEIN STRUCTURE; VIRUS NEUTRALIZATION; VIRUS PARTICLE; WESTERN BLOTTING;

BOVINE PAPILLOMAVIRUS-LIKE PARTICLE; HIV-1; MEMBRANE-PROXIMAL EXTERNAL REGION; MUCOSAL; NEUTRALIZING ANTIBODY; VACCINE;

ADMINISTRATION, ORAL; AIDS VACCINES; ANIMALS; CATTLE; DRUG CARRIERS; EPITOPES; FEMALE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP41; HIV-1; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A, SECRETORY; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; PAPILLOMAVIRIDAE; VACCINES, SYNTHETIC; VACCINES, VIRUS-LIKE PARTICLE;

EID: 84886096664     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.09.003     Document Type: Article

References (54)

1. Fuchs J.D., Sobieszczyk M.E., Hammer S.M., Buchbinder S.P. Lessons drawn from recent HIV vaccine efficacy trials. J Acquir Immune Defic Syndr 2010, 55(Suppl. (2)):S128-S131.
2. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009, 361(23):2209-2220.
3. Burton D.R., Pyati J., Koduri R., Sharp S.J., Thornton G.B., Parren P.W., et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994, 266(5187):1024-1027.
4. Kessler J.A., McKenna P.M., Emini E.A., Chan C.P., Patel M.D., Gupta S.K., et al. Recombinant human monoclonal antibody IgG1b12 neutralizes diverse human immunodeficiency virus type 1 primary isolates. AIDS Res Hum Retroviruses 1997, 13(7):575-582.
5. Li Y., Migueles S.A., Welcher B., Svehla K., Phogat A., Louder M.K., et al. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med 2007, 13(9):1032-1034.
6. Pilgrim A.K., Pantaleo G., Cohen O.J., Fink L.M., Zhou J.Y., Zhou J.T., et al. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J Infect Dis 1997, 176(4):924-932.
7. Wu X., Yang Z.Y., Li Y., Hogerkorp C.M., Schief W.R., Seaman M.S., et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010, 329(5993):856-861.
8. Walker L.M., Phogat S.K., Chan-Hui P.Y., Wagner D., Phung P., Goss J.L., et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009, 326(5950):285-289.
9. Scheid J.F., Mouquet H., Ueberheide B., Diskin R., Klein F., Oliveira T.Y., et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 2011, 333(6049):1633-1637.
10. Bonsignori M., Hwang K.K., Chen X., Tsao C.Y., Morris L., Gray E., et al. Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol 2011, 85(19):9998-10009.
11. Wu X., Zhou T., Zhu J., Zhang B., Georgiev I., Wang C., et al. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 2011, 333(6049):1593-1602.
12. Huang J., Ofek G., Laub L., Louder M.K., Doria-Rose N.A., Longo N.S., et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 2012, 491(7424):406-412.
13. Conley A.J., Kessler J.A., Boots L.J., Tung J.S., Arnold B.A., Keller P.M., et al. Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody. Proc Natl Acad Sci U S A 1994, 91(8):3348-3352.
14. Muster T., Steindl F., Purtscher M., Trkola A., Klima A., Himmler G., et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 1993, 67(11):6642-6647.
15. Zwick M.B., Labrijn A.F., Wang M., Spenlehauer C., Saphire E.O., Binley J.M., et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 2001, 75(22):10892-10905.
16. Cardoso R.M., Brunel F.M., Ferguson S., Zwick M., Burton D.R., Dawson P.E., et al. Structural basis of enhanced binding of extended and helically constrained peptide epitopes of the broadly neutralizing HIV-1 antibody 4E10. J Mol Biol 2007, 365(5):1533-1544.
17. Julien J.P., Bryson S., Nieva J.L., Pai E.F. Structural details of HIV-1 recognition by the broadly neutralizing monoclonal antibody 2F5: epitope conformation, antigen-recognition loop mobility, and anion-binding site. J Mol Biol 2008, 384(2):377-392.
18. Ofek G., Tang M., Sambor A., Katinger H., Mascola J.R., Wyatt R., et al. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J Virol 2004, 78(19):10724-10737.
19. Sun Z.Y., Oh K.J., Kim M., Yu J., Brusic V., Song L., et al. HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane. Immunity 2008, 28(1):52-63.
20. Brunel F.M., Zwick M.B., Cardoso R.M., Nelson J.D., Wilson I.A., Burton D.R., et al. Structure-function analysis of the epitope for 4E10, a broadly neutralizing human immunodeficiency virus type 1 antibody. J Virol 2006, 80(4):1680-1687.
21. Cardoso R.M., Zwick M.B., Stanfield R.L., Kunert R., Binley J.M., Katinger H., et al. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity 2005, 22(2):163-173.
22. Coeffier E., Clement J.M., Cussac V., Khodaei-Boorane N., Jehanno M., Rojas M., et al. Antigenicity and immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE protein. Vaccine 2000, 19(7-8):684-693.
23. Eckhart L., Raffelsberger W., Ferko B., Klima A., Purtscher M., Katinger H., et al. Immunogenic presentation of a conserved gp41 epitope of human immunodeficiency virus type 1 on recombinant surface antigen of hepatitis B virus. J Gen Virol 1996, 77(Pt 9):2001-2008.
24. Ho J., MacDonald K.S., Barber B.H. Construction of recombinant targeting immunogens incorporating an HIV-1 neutralizing epitope into sites of differing conformational constraint. Vaccine 2002, 20(7-8):1169-1180.
25. Phogat S., Svehla K., Tang M., Spadaccini A., Muller J., Mascola J., et al. Analysis of the human immunodeficiency virus type 1 gp41 membrane proximal external region arrayed on hepatitis B surface antigen particles. Virology 2008, 373(1):72-84.
26. Wang Z., Liu Z., Cheng X., Chen Y.H. The recombinant immunogen with high-density epitopes of ELDKWA and ELDEWA induced antibodies recognizing both epitopes on HIV-1 gp41. Microbiol Immunol 2005, 49(8):703-709.
27. Zhang H., Huang Y., Fayad R., Spear G.T., Qiao L. Induction of mucosal and systemic neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) by oral immunization with bovine Papillomavirus-HIV-1 gp41 chimeric virus-like particles. J Virol 2004, 78(15):8342-8348.
28. Arnold G.F., Velasco P.K., Holmes A.K., Wrin T., Geisler S.C., Phung P., et al. Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitope. J Virol 2009, 83(10):5087-5100.
29. Wang J., Tong P., Lu L., Zhou L., Xu L., Jiang S., et al. HIV-1 gp41 core with exposed membrane-proximal external region inducing broad HIV-1 neutralizing antibodies. PLoS ONE 2011, 6(3):e18233.
30. Ambrose Z., Larsen K., Thompson J., Stevens Y., Finn E., Hu S.L., et al. Evidence for early local viral replication and local production of antiviral immunity upon mucosal simian-human immunodeficiency virus SHIV(89.6) infection in Macaca nemestrina. J Virol 2001, 75(18):8589-8596.
31. Mantis N.J., Kozlowski P.A., Mielcarz D.W., Weissenhorn W., Neutra M.R. Immunization of mice with recombinant gp41 in a systemic prime/mucosal boost protocol induces HIV-1-specific serum IgG and secretory IgA antibodies. Vaccine 2001, 19(28-29):3990-4001.
32. Letvin N.L. Strategies for an HIV vaccine. J Clin Invest 2002, 110(1):15-20.
33. Liu X.S., Abdul-Jabbar I., Qi Y.M., Frazer I.H., Zhou J. Mucosal immunisation with papillomavirus virus-like particles elicits systemic and mucosal immunity in mice. Virology 1998, 252(1):39-45.
34. Shi W., Liu J., Huang Y., Qiao L. Papillomavirus pseudovirus: a novel vaccine to induce mucosal and systemic cytotoxic T-lymphocyte responses. J Virol 2001, 75(21):10139-10148.
35. Zhang H., Fayad R., Wang X., Quinn D., Qiao L. Human immunodeficiency virus type 1 gag-specific mucosal immunity after oral immunization with papillomavirus pseudoviruses encoding gag. J Virol 2004, 78(19):10249-10257.
36. Huang Y., Fayad R., Smock A., Ullrich A.M., Qiao L. Induction of mucosal and systemic immune responses against human carcinoembryonic antigen by an oral vaccine. Cancer Res 2005, 65(15):6990-6999.
37. Chackerian B., Lowy D.R., Schiller J.T. Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles. Proc Natl Acad Sci U S A 1999, 96(5):2373-2378.
38. Mann D.L., O'Brien S.J., Gilbert D.A., Reid Y., Popovic M., Read-Connole E., et al. Origin of the HIV-susceptible human CD4+ cell line H9. AIDS Res Hum Retroviruses 1989, 5(3):253-255.
39. Popovic M., Read-Connole E., Gallo R.C. T4 positive human neoplastic cell lines susceptible to and permissive for HTLV-III. Lancet 1984, 2(8417-8418):1472-1473.
40. Paintsil J., Muller M., Picken M., Gissmann L., Zhou J. Carboxyl terminus of bovine papillomavirus type-1 L1 protein is not required for capsid formation. Virology 1996, 223(1):238-244.
41. Buchacher A., Predl R., Strutzenberger K., Steinfellner W., Trkola A., Purtscher M., et al. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res Hum Retroviruses 1994, 10(4):359-369.
42. Purtscher M., Trkola A., Grassauer A., Schulz P.M., Klima A., Dopper S., et al. Restricted antigenic variability of the epitope recognized by the neutralizing gp41 antibody 2F5. Aids 1996, 10(6):587-593.
43. Purtscher M., Trkola A., Gruber G., Buchacher A., Predl R., Steindl F., et al. A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 1994, 10(12):1651-1658.
44. Brown B.K., Darden J.M., Tovanabutra S., Oblander T., Frost J., Sanders-Buell E., et al. Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01_AE, and CRF02_AG, for the development and assessment of candidate vaccines. J Virol 2005, 79(10):6089-6101.
45. Hart M.L., Saifuddin M., Spear G.T. Glycosylation inhibitors and neuraminidase enhance human immunodeficiency virus type 1 binding and neutralization by mannose-binding lectin. J Gen Virol 2003, 84(Pt 2):353-360.
46. Chackerian B., Briglio L., Albert P.S., Lowy D.R., Schiller J.T. Induction of autoantibodies to CCR5 in macaques and subsequent effects upon challenge with an R5-tropic simian/human immunodeficiency virus. J Virol 2004, 78(8):4037-4047.
47. Haynes B.F., Fleming J., St Clair E.W., Katinger H., Stiegler G., Kunert R., et al. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 2005, 308(5730):1906-1908.
48. Yang G., Holl T.M., Liu Y., Li Y., Lu X., Nicely N.I., et al. Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies. J Exp Med 2013, 210(2):241-256.
49. Pastori C., Tudor D., Diomede L., Drillet A.S., Jegerlehner A., Rohn T.A., et al. Virus like particle based strategy to elicit HIV-protective antibodies to the alpha-helic regions of gp41. Virology 2012, 431(1-2):1-11.
50. Devito C., Broliden K., Kaul R., Svensson L., Johansen K., Kiama P., et al. Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells. J Immunol 2000, 165(9):5170-5176.
51. Tudor D., Derrien M., Diomede L., Drillet A.S., Houimel M., Moog C., et al. HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4(+) cell infection: an IgA gene and functional analysis. Mucosal Immunol 2009, 2(5):412-426.
52. Revaz V., Zurbriggen R., Moser C., Schiller J.T., Ponci F., Bobst M., et al. Humoral and cellular immune responses to airway immunization of mice with human papillomavirus type 16 virus-like particles and mucosal adjuvants. Antiviral Res 2007, 76(1):75-85.
53. Cho H.J., Kim J.Y., Lee Y., Kim J.M., Kim Y.B., Chun T., et al. Enhanced humoral and cellular immune responses after sublingual immunization against human papillomavirus 16 L1 protein with adjuvants. Vaccine 2010, 28(14):2598-2606.
54. Binley J.M., Wrin T., Korber B., Zwick M.B., Wang M., Chappey C., et al. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol 2004, 78(23):13232-13252.